Payment overview · 2025
General Payments
$608.51
30 reported records · 10 companies
Healthcare provider profile · identity verified
Suzanne B Grimm, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · WISCONSIN RAPIDS, WI · NPI 1245345230
Verified facts
What the public records show
CMS Open Payments records show Suzanne B Grimm, MD received $608.51 in general payments during 2025 across 30 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 23.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abilify Asimtufii, Abilify Maintena, Aristada, Ingrezza, Lybalvi, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Vraylar by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Aristada by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lybalvi by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY ASIMTUFII as an associated drug or biological on 4974 records involving 1745 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Abilify Asimtufii by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY ASIMTUFII as an associated drug or biological on 37017 records involving 12446 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Abilify Asimtufii by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $144.73 | 23.8% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $78.09 | 12.8% | 4 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $70.29 | 11.6% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $63.44 | 10.4% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $57.58 | 9.5% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $57.04 | 9.4% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $44.83 | 7.4% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $37.18 | 6.1% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $36.21 | 6.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.12 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $608.51 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $119.61 | 4 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $107.08 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $78.09 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $63.44 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $57.58 | 3 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $57.04 | 3 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $51.60 | 3 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $44.83 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $37.18 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $25.12 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.12 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $17.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABILIFY ASIMTUFII abilify asimtufii |
2025 | Abilify Asimtufii | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ABILIFY MAINTENA abilify maintena |
2025 | Abilify Maintena | 2024 | 99 | exact normalized | Medicare Part D |
| ARISTADA aristada |
2025 | Aristada | 2024 | 64 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LYBALVI lybalvi |
2025 | Lybalvi | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | ARISTADA open payments reported associated product |
CMS Open Payments — General Payments 76041 supporting records · 17486 recipient NPIs · example record 1222428566 |
Aristada · 2024 Exact normalized brand match · 1 Part D row |
64 | 12 |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | LYBALVI open payments reported associated product |
CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566 |
Lybalvi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY ASIMTUFII open payments reported associated product |
CMS Open Payments — General Payments 4974 supporting records · 1745 recipient NPIs · example record 1251759998 |
Abilify Asimtufii · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
99 | 13 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY ASIMTUFII open payments reported associated product |
CMS Open Payments — General Payments 37017 supporting records · 12446 recipient NPIs · example record 1227267748 |
Abilify Asimtufii · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
99 | 13 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Quetiapine Fumarate | Quetiapine Fumarate | 380 | 31 |
| Clozapine | Clozapine | 369 | 20 |
| Olanzapine | Olanzapine | 308 | 27 |
| Clonazepam | Clonazepam | 275 | 30 |
| Lorazepam | Lorazepam | 262 | 31 |
| Lamotrigine | Lamotrigine | 253 | 32 |
| Mirtazapine | Mirtazapine | 243 | 30 |
| Trazodone Hcl | Trazodone Hcl | 223 | 28 |
| Aripiprazole | Aripiprazole | 181 | 30 |
| Sertraline Hcl | Sertraline Hcl | 167 | 21 |
| Divalproex Sodium Er | Divalproex Sodium | 161 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 152 | 24 |
| Benztropine Mesylate | Benztropine Mesylate | 146 | 16 |
| Divalproex Sodium | Divalproex Sodium | 144 | 13 |
| Risperidone | Risperidone | 129 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 125 | 15 |
| Alprazolam | Alprazolam | 124 | 14 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 117 | 13 |
| Paliperidone Er | Paliperidone | 105 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 15 |
| Buspirone Hcl | Buspirone Hcl | 102 | 14 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 102 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 15 |
| Abilify Maintena | Aripiprazole | 99 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 92 | 14 |
| Lithium Carbonate | Lithium Carbonate | 90 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 83 | 15 |
| Vyvanse | Lisdexamfetamine Dimesylate | 70 | suppressed |
| Gabapentin | Gabapentin | 67 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 65 | suppressed |
| Aristada | Aripiprazole Lauroxil | 64 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 60 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 57 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 57 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 56 | suppressed |
| Belsomra | Suvorexant | 53 | suppressed |
| Ingrezza | Valbenazine Tosylate | 53 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 50 | suppressed |
| Vraylar | Cariprazine Hcl | 49 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 47 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 47 | suppressed |
| Haloperidol | Haloperidol | 46 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 45 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 45 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 42 | suppressed |
| Alprazolam Er | Alprazolam | 40 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 40 | suppressed |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 39 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 39 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 39 | suppressed |
| Invega Trinza | Paliperidone Palmitate | 38 | suppressed |
| Loxapine | Loxapine Succinate | 38 | suppressed |
| Modafinil | Modafinil | 38 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 37 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 35 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 31 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 29 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 29 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 25 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 25 | suppressed |
| Olanzapine Odt | Olanzapine | 25 | suppressed |
| Dexmethylphenidate Hcl Er | Dexmethylphenidate Hcl | 24 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Rexulti | Brexpiprazole | 19 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 17 | suppressed |
| Perseris | Risperidone | 17 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 17 | suppressed |
| Amantadine | Amantadine Hcl | 16 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 15 | suppressed |
| Zaleplon | Zaleplon | 15 | suppressed |
| Abilify Asimtufii | Aripiprazole | 14 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 13 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 13 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 12 | suppressed |
| Lybalvi | Olanzapine/Samidorphan Malate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $608.51 · 30 records | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, Auvelity, CAPLYTA, COBENFY, FANAPT, INGREZZA, LYBALVI, REXULTI, UZEDY, VIVITROL, VRAYLAR | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abilify Asimtufii play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error